- Programme Area 2
Pharmacoepidemiology
- Disease register
- Long-term safety
- Therapy effectiveness
Benefits and Risks of New Therapies.
With the help of large clinical-epidemiological cohort studies, the pharmacoepidemiology group examines the long-term safety and effectiveness of new rheumatic medications. Our goal is to provide doctors and patients with reliable evidence on the safety profile under real-world conditions, thereby increasing treatment safety for risk groups as well.
The group continuously develops both the technical requirements for data collection (online registers, patient apps, automated monitoring) and the methodological foundations for data analysis.